Cuban Lung Cancer Vaccine Receives Creativity and Technical Innovation Award 2015

Édité par Ivan Martínez
2015-11-19 14:23:08

Pinterest
Telegram
Linkedin
WhatsApp

Havana, November 19 (RHC)-- Cuba's Industrial Property Office has presented the Cuban advanced lung cancer vaccine, developed by the Havana-based Molecular Immunology Center, with the Creativity and Technical Innovation Award 2015.

Registered in Cuba since 2012, the product called Vaxira, has a very favorable impact of the patients' survival rate and quality of life, while no side-effects have been reported.

Vaxira is now registered in 17 countries. Studies are currently underway to assess its impact on patients suffering from breast and ovarian cancers.



Commentaires


Laissez un commentaire
Tous les champs sont requis
Votre commentaire ne sera pas publié
captcha challenge
up